Inhaled Insulin: An Overview

Features

Clinical Diabetes 2001 Jan; 19(1): 13-16. https://doi.org/10.2337/diaclin.19.1.13

Article Figures & Tables

Table 1.

Summary of Phase 2 Trials

Patient Type	N	Duration of study (not including run-in period)	Treatment arm/change in HbA_1c from baseline	Reference
Type 2	51	3 months	• Inhaled insulin/0.7%	12
			• Subcutaneous insulin/0.7%

Type 2	62	3 months	• Oral agent/0.13%	13
			• Oral agent plus inhaled insulin/2.28%

Type 1	70	3 months	• Subcutaneous insulin (2–3 injections/day)/0.83%	14
			• Inhaled insulin plus subcutaneous insulin (once daily)/0.64%